A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
Chan, J.A., Blaszkowsky, L.S., Enzinger, P.C., Ryan, D.P., Abrams, T.A., Zhu, A.X., Temel, J.S., Schrag, D., Bhargava, P., Meyerhardt, J.A., Wolpin, B.M., Fidias, P., Zheng, H., Florio, S., Regan, E., Fuchs, C.S.
Published in Annals of oncology (01.06.2011)
Published in Annals of oncology (01.06.2011)
Get full text
Journal Article
SO-26 Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients
Corcoran, R., Giannakis, M., Allen, J., Chen, J., Pelka, K., Chao, S., Meyerhardt, J., Enzinger, A., Enzinger, P., McCleary, N., Yugelun, M., Abrams, T., Kanter, K., Van Seventer, E., Bradford, W., Fetter, I., Siravegna, G., Tian, J., Clark, J., Ryan, D., Hacohen, N., Parikh, A.
Published in Annals of oncology (01.07.2020)
Published in Annals of oncology (01.07.2020)
Get full text
Journal Article
The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer
Metges, J., François, E., Shah, M., Adenis, A., Enzinger, P., Kojima, T., Muro, K., Bennouna, J., Hsu, C., Moriwaki, T., Kim, S., Lee, S., Kato, K., Shen, L., Qin, S., Ferreira, P., Wang, R., Bhagia, P., Kang, S., Doi, T.
Published in Annals of oncology (01.07.2019)
Published in Annals of oncology (01.07.2019)
Get full text
Journal Article
A phase 3 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590 - Trial in progress
Kato, K., Shah, M., Enzinger, P., Bennouna, J., Shen, L., Adenis, A., Sun, J., Cho, B., Ozguroglu, M., Kojima, T., Kostorov, V., Hierro, C., Zhu, Y., Shah, S., Bhagia, P., Doi, T.
Published in Annals of oncology (01.06.2018)
Published in Annals of oncology (01.06.2018)
Get full text
Journal Article
Phase III KEYNOTE-590 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer
Kato, K., Shah, M.A., Enzinger, P.C., Bennouna, J., Shen, L., Adenis, A., Sun, J.-M., Cho, B.C., Ozguroglu, M., Kojima, T., Kostorov, V., Hierro, C., Zhu, Y., Shah, S., Bhagia, P., Doi, T.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA)
Catenacci, D.V.T., Park, H., Uronis, H.E., Kang, Y.-K., Ng, M., Gold, P., Lacy, J., Enzinger, P.C., Park, S., Lee, K.-W., Yen, J., Odegaard, J., Franovic, A., Baughman, J., Muth, J., Wynter-Horton, A., Wu, T., Wigginton, J., Davidson-Moncada, J.K., Bang, Y.-J.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer
Sanford, N. N., Catalano, P. J., Enzinger, P. C., King, B. L., Bueno, R., Martin, N. E., Hong, T. S., Wo, J. Y., Mamon, H. J.
Published in Diseases of the esophagus (01.07.2017)
Published in Diseases of the esophagus (01.07.2017)
Get full text
Journal Article
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer
Meyerhardt, JA, Stuart, K, Fuchs, CS, Zhu, AX, Earle, CC, Bhargava, P, Blaszkowsky, L, Enzinger, P, Mayer, RJ, Battu, S, Lawrence, C, Ryan, DP
Published in Annals of oncology (01.07.2007)
Published in Annals of oncology (01.07.2007)
Get full text
Journal Article
Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer
Enzinger, P. C., Ryan, D. P., Clark, J. W., Muzikansky, A., Earle, C. C., Kulke, M. H., Meyerhardt, J. A., Blaszkowsky, L. S., Zhu, A. X., Fidias, P., Vincitore, M. M., Mayer, R. J., Fuchs, C. S.
Published in Annals of oncology (01.03.2009)
Published in Annals of oncology (01.03.2009)
Get full text
Journal Article
P-285 Q-TWiST analysis for pembrolizumab plus chemotherapy versus chemotherapy as first-line treatment for patients with advanced esophageal cancer in the KEYNOTE-590 study
Díez García, M., Shah, S., Joo, S., Valderrama, A., Zhang, S., Zhang, Y., Enzinger, P.
Published in Annals of oncology (01.06.2022)
Published in Annals of oncology (01.06.2022)
Get full text
Journal Article
Clinical and Genomic Characterization of Esophageal Cancer Brain Metastases
Yang, D.D., Papke, D.J., Kang, H., Aizer, A.A., Lamba, N., Kozono, D.E., Wee, J.O., Enzinger, P., Mamon, H.J.
Published in International journal of radiation oncology, biology, physics (01.11.2022)
Published in International journal of radiation oncology, biology, physics (01.11.2022)
Get full text
Journal Article
A Single-Institution Experience of Acute Neuropathic Lumbosacral Pain in Patients Treated with Short Course Hypofractionated Radiotherapy in Locally Advanced Rectal Cancer
Lee, K.N., Neibart, S.S., Droznin, A., Guthier, C.V., Martin, N.E., Mancias, J.D., Lam, M., Shiloh, R., Peng, L.C., Ng, K., Surana, R., Enzinger, P., Meyerhardt, J., Mamon, H.J.
Published in International journal of radiation oncology, biology, physics (01.10.2023)
Published in International journal of radiation oncology, biology, physics (01.10.2023)
Get full text
Journal Article
P-298 Open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress
Sun, J., Enzinger, P., Adenis, A., Shah, M., Kato, K., Bennouna, J., Doi, T., Hawk, N., Yu, L., Shah, S., Bhagia, P., Shen, L.
Published in Annals of oncology (01.06.2022)
Published in Annals of oncology (01.06.2022)
Get full text
Journal Article
SO-11 Bemarituzumab for treatment of previously untreated advanced and/or metastatic gastric and gastroesophageal cancer (GC): Final analysis of a randomized phase 2 trial (FIGHT)
Wainberg, Z., Kang, Y., Lee, K., Qin, S., Yamaguchi, K., Kim, I., Saeed, A., Oh, S., Li, J., Turk, H., Teixeira, A., Hitre, E., Udrea, A., Cardellino, G., Sanchez, R. Guardeño, Zahlten-Kümeli, A., Taylor, K., Enzinger, P.
Published in Annals of oncology (01.06.2023)
Published in Annals of oncology (01.06.2023)
Get full text
Journal Article
SO-38 Clinical efficacy and single-cell analysis of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients
Corcoran, R., Tian, J., Chen, J., Chao, S., Pelka, K., Baiev, I., Sindurakar, P., Allen, J., Meyerhardt, J., Enzinger, A., Enzinger, P., McCleary, N., Klempner, S., Yurgelun, M., Abrams, T., Clark, J., Ryan, D., Giannakis, M., Parikh, A., Hacohen, N.
Published in Annals of oncology (01.06.2022)
Published in Annals of oncology (01.06.2022)
Get full text
Journal Article
P-34 The randomized, double-blind, placebo-controlled phase 3 trial KEYNOTE-975: Pembrolizumab vs placebo in patients with esophageal carcinoma receiving concurrent definitive chemoradiotherapy
Moehler, M., Enzinger, P., Bennouna, J., Doi, T., Shen, L., Kato, K., Adenis, A., Mamon, H., Fu, X., Cho, B., Desai, A., Bhagia, P., Shih, C., Shah, M.
Published in Annals of oncology (01.07.2020)
Published in Annals of oncology (01.07.2020)
Get full text
Journal Article
GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Xu, R.-H., Dongsheng, Z., Ajani, J., Al-Batran, S.-E., Bang, Y.-J., Catenacci, D., Enzinger, P., Ilson, D., Kim, S., Lordick, F., Shitara, K., Van Cutsem, E., Arozullah, A., Wook Park, J., Shah, M.
Published in Annals of oncology (01.11.2019)
Published in Annals of oncology (01.11.2019)
Get full text
Journal Article
SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Yamaguchi, K., Shitara, K., Al-Batran, S.-E., Bang, Y.-J., Catenacci, D., Enzinger, P., Ilson, D., Kim, S., Lordick, F., Shah, M., Van Cutsem, E., Xu, R.-H., Arozullah, A., Wook Park, J., Ajani, J.
Published in Annals of oncology (01.11.2019)
Published in Annals of oncology (01.11.2019)
Get full text
Journal Article